![](https://investorshub.advfn.com/uicon/276021.png?cb=1471598439)
Tuesday, September 06, 2011 9:57:31 AM
Like a number of other growing companies, VistaGen Therapeutics, a biotech company applying stem cell technology for drug rescue and cell therapy, plans to use the OTC Bulletin Board as an important starting point for a move to the NYSE Amex or NASDAQ. In its efforts to access capital markets and raise awareness, the company sees such a move as important for expanding visibility and growing its investor base. Biotech companies that have recently followed a similar path include Neoprobe Corp. (NEOP), which successfully made the leap from OTCBB to the NYSE Amex earlier this year, and Echo Therapeutics (ECTE), which recently moved from the OTCBB to Nasdaq. [NOTE: ECTE reflects the march to Nasdaq very well, and its post-listing volume is much more reflective of what VistaGen aspires to achieve near term.]
Following its successful strategic financing in May, VistaGen is now ready to put its advanced stem cell technology platform to work after twelve years of extensive research and development. VistaGen’s platform combines several technologies, including stem cell technologies developed by VistaGen and renowned Canadian scientist, Dr. Gordon Keller, the Chairman of VistaGen’s Scientific Advisory Board and Director of the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto. One valuable commercial application of VistaGen’s technology involves using mature human cells derived from pluripotent stem cells to create a new generation of biological assays for drug screening. It’s part of an effort to rescue once promising drug candidates that have proven efficacy but which were shelved by pharmaceutical companies due to toxicity issues.
VistaGen’s first target market is heart toxicity, an area of primary concern and potential. The Company’s human heart cell-based CardioSafe 3D bioassay system provides clinically relevant predictive data before human use, thereby preventing serious safety problems seen with such widely-marketed products as Merck’s Vioxx or GlaxoSmithKline’s Avandia. VistaGen is looking to rescue drug candidates that have established efficacy and millions dollars in research behind them, offering huge potential when brought back on track through carefully performed re-engineering using a combination of its stem cell technology and modern medicinal chemistry.
Besides drug rescue, VistaGen is also using its stem cell technologies to advance its preclinical cell therapy programs for applications in autologous bone marrow transplantation and heart, liver, and cartilage repair. In addition, its AV-101 prodrug candidate is in clinical development for treatment of neuropathic pain and other neurological disorders such as epilepsy, and Parkinson’s disease and depression.
Recent VTGN News
- Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine • Business Wire • 07/09/2024 12:30:00 PM
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM